clinical trial · NCT07107373
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
Bristol-Myers Squibb·—·active not recruiting·n = 150
Obstructive Hypertrophic Cardiomyopathy (oHCM)Mavacamten
brief summary
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
started
Dec 22, 2023
primary completion
Jul 26, 2024
completion
Dec 31, 2027
last updated
Sep 30, 2026
official title
MavAcamten Real World eVidEnce coLlaboration in HCM (MARVEL-HCM)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol